Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PLB1004 + Vebreltinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PLB1004 | PLB 1004|PLB-1004 | EGFR Exon 20 Insertion Inhibitor 15 EGFR Inhibitor (Pan) 63 | PLB1004 is an EGFR inhibitor with activity against L858R, T790M, exon 19 deletions, and exon 20 insertion mutations, which potentially decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): CT102). | |
| Vebreltinib | Bozitinib|PLB1001|PLB-1001|APL-101|APL 101|APL101 | MET Inhibitor 59 | Vebreltinib (PLB-1001) is an ATP-competitive, small molecule inhibitor of MET, which is able to permeate the blood brain barrier and may inhibit downstream signaling and block tumor growth (PMID: 30343896). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|